Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 11, 2004, Pages 2209-2220

  Doggrell, Sheila A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Doggrell Biomedical Communications   (New Zealand)

Author keywords

7 hexanoyltaxol; Clinical trials; Paclitaxel; Restenosis; SIRIUS; Sirolimus; Stents; TAXUS

Indexed keywords

7 HEXANOLYTAXOL; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; CLOPIDOGREL; CONTRAST MEDIUM; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; IMMUNOSUPPRESSIVE AGENT; IOPROMIDE; PACLITAXEL; PACLITAXEL DERIVATIVE; POLYMER; RAPAMYCIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTERY DIAMETER; ARTERY ENDOTHELIUM; ARTERY LESION; BIOLOGICAL MODEL; CAPILLARY; CLINICAL PRACTICE; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG USE; HEART DEATH; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MATERIAL COATING; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REGISTER; RESTENOSIS; REVIEW; SLOW RELEASE FORMULATION; TREATMENT OUTCOME;

ANIMALS; BRIDGED COMPOUNDS; CLINICAL TRIALS; CORONARY RESTENOSIS; HUMANS; MYOCARDIAL REVASCULARIZATION; PACLITAXEL; SIROLIMUS; STENTS;

EID: 8544219738     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.11.2209     Document Type: Review

References (68)

1. SERRUYS PW, DE JAEGERE P, KIEMENEJI F et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benstent Study Group. N. Engl. J. Med. (1994) 331:489-495.
2. MACAYA C, SERRUYS PW, RUYGROK P et al.: Continued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. J. Am. Coll. Cardiol. (1996) 27:255-262.
3. KIEMENEIJ F, SERRUYS PW, MACAYA C et al.: Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Besestent-I trial. J. Am. Coll. Cardiol, (2001) 37: 1598-1603.
4. FISCHMAN DL, LEON MB, BAIM DS et al.: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N. Engl J. Med. (1994) 331: 496-501.
5. SAVAGE MP, FISCHMAN L, RAKE R et al.: Efficacy of coronary stenting versus balloon angioplasty in small coronary arteries. Stent Restenosis Study (STRESS) Investigators. J. Am. Coll. Cardiol. (1998) 31: 307-311.
6. ELEZI S, KASTRATI A, PACHE J et al.: Diabetes mellitus and the clinical and angiographic outcomes after coronary stent placement. J. Am. Coll. Cardiol. (1998) 32: 1866-1873.
7. ELEZI S, KASTRATI A, NEUMANN FJ et al.: Vessel size and long-term outcome after coronary stent placement. Circulation (1998) 98:1875-1880.
8. KASTRATI A, ELEZI S, DIRCHINGER J et al.: Influence of lesion length on restenosis after coronary artery replacement. Am. J. Cardiol. (1999) 83:651-659.
9. KOBAYASHI Y, DE GREGORIO J, KOBAYASHI N et al.: Stented segment length as an independent predictor of restenosis. J. Am. Coll. Cardiol. (1999) 34:651-659.
10. SOLLOTT SJ, CHENG L, PAULY RR et al.: Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J. Clin. Invest. (1995) 95:1869-1876.
11. MARK SO, MARKS AR: Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation (2001) 104:1188-1193.
12. GREGORY CR, HUANG X, PRATT RE et al.: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelium replacement. Transplantation (1995) 59:655-661.
13. GALLO R, PADUREAN A, JAYARAMAN T et al.: Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation (1999) 99:2164-2170.
14. BURKE SE, LUBBERS NL, CHEN YM et al.: Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J. Cardiovasc. Pharmacol. (1999) 33: 29-835.
15. SUZUKI T, KOPIA G, HAYAHI S et al.: Stent-based delivery of sirolimus reduced neointimal formation in a porcine coronary artery. Circulation (2001) 104:1188-1193.
16. SOUSA JE, COSTA MA, ABIZAID A et al.: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries. A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation (2001) 103:192-195.
17. SOUSA JE, COSTA MA, ABIZAID AC et al.: Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One-year angiographic and intravascular ultrasound follow-up. Circulation (2001) 104:2007-2011.
18. SOUSA JE, COSTA MA, SOUSA AG et al.: Two-year Angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation (2003) 107:381-383.
19. DEGERTEKIN M, SERRUYS PW, FOLEY DP et al.: Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, Angiographic, and intravascular ultrasound follow-up. Circulation (2002) 106: 610-1613.
20. MORICE M-C, SERRUYS PW, SOUSA JE et al.: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularisation. N. Engl. J. Med. (2002) 346: 773-1780.
21. REGAR E, SERRUYS PW, BODE C et al.: Angiographic findings of the multicentre Randomized Study with the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation (2002) 106:1949-1959.
22. SERRUYS PW, DEGERTEKIN M, TANABE K et al.: Intravascular ultasound findings in the multicentre, randomised, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation (2002) 106: 98-803.
23. DEGERTEKIN M, SERRUYS PW, TANABE K et al.: Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation (2003) 108: 2747-2750.
24. ABIZAID A, COSTA MA, BLANCHARD D et al.: Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL trial. Eur. Heart J. (2004) 25:107-112.
25. MOSES JW, LEON MB, POPMA JJ et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native corortary artery. N. Engl. J. Med. (2003) 349:1315-1325.
26. MOUSSA I, LEON MB, BAIM DS et al.: Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRollmUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation (2004) 109:2273-2278.
27. HOLMES DR Jr, LEON MB, MOSES JW et al.: Analysis of 1-year clinical outcomes in the Sirius trial: a randomised trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation (2004) 109:634-640.
28. SCHOFER J, SCHLUTER M, GERSHLICK AH et al.: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind randomised controlled trial (E-SIRIUS). Lancet (2003) 362: 093-1099.
29. SCHAMPAERT E, COHEN EA, SCHLUTER M et al.: The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J. Am. Coll. Cardiol. (2004) 43:1110-1115.
30. LEMOS PA, LEE CH, DEGERTEKIN M et al.: Early outcome after sitolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J. Am. Coll. Cardiol. (2003) 41:2093-2099.
31. LEMOS PA, SERRUYS PW, VAN DOMBURG RT et al.: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare-stent implantation in the 'real world': the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation (2004) 109:190-195.
32. LEMOS PA, SAIA F, LIGTHART JMR et al.: Coronary restenosis after sirolimus-eluting stent implantation. Morphological description and mechanistic analysis from a consecutive series of cases. Circulation (2003) 108:257-260.
33. SAIA F, LEMOS PA, LEE CH et al.: Sirolimus-eluting stent implantation in ST-elevation acute MI: a clinical and Angiographic study. Circulation (2003) 108:1927-1929.
34. LEMOS PA, SAIA F, HOFMA SH et al.: Short- and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare-stents for patients with acute MI. J. Am. Coll. Cardiol. (2004) 43:704-708.
35. LEMOS PA, HOYE A, GOEDHART D et al.: Clinical, Angiographic, and procedural predictors of Angiographic restenosis after sirolimus-eluting stent implantation in comples patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation (2004) 109:1366-1370.
36. HOYE A, LEMOS PA, ARAMPATZIS CA et al.: Effectiveness of the sirolimus-eluting stent in the treatment of patients with a prior history of coronary artery bypass graft surgery. Coron. Artery Dis. (2004) 15:171-175.
37. SOUSA JE, COSTA MA, ABIZAID A et al.: Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation (2003) 103:24-27.
38. DEGERTEKIN M, REGAR E, TANABE K et al.: Sorolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J. Am. Coll. Cardiol. (2003) 41: 84-189.
39. DEGERTEKIN M, LEMOS PA, LEE CH et al.: Intravascular ultrasound evaluation after sirolimus-eluting stent implantation for de novo and in-stent restenosis lesions. Eur. Heart J. (2004) 25:32-38.
40. LEMOS PA, VAN MIEGHEM CA, ARAMPATZIS CA et al.: Post-sirolimus-eluting stent restenosis treated with repeat percutaneous intervention: late Angiographic and clinical outcomes. Circulation (2004) 109:2500-2502.
41. ROWINSKY EK, DONEHOWER RC: Paclitaxel (taxol). N. Engl. J. Med. (1995) 332:1004-1014.
42. AXEL DI, KUNERT W, GÖGGELLMANN C et al.: Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation (1997) 96: 36-645.
43. BAUMBACH A, HERDEG C, KLUGE M et al.: Local drug delivery: impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall. Catheter Cardiovasc. Interv. (1999) 47:103-106.
44. OBERHOFF M, KUNERT W, HERDEG C et al.: Inhibition of smooth muscle cell proliferation after local drug delivery of the antimitotic drug paclitaxel using a porous balloon catheter. Basic Res. Cardiol. (2001) 96:275-282.
45. OBERHOFF M, HERDEG C, AL GHOBAINY R et al.: Local delivery of paclitaxel using the double-balloon perfusion catheter before stenting in the porcine coronary artery. Catheter Cardiovasc. Interv. (2001) 53:562-568.
46. HELDMAN AW, CHENG L, JENKINS M et al.: Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation (2001) 103:2289-2295.
47. VAN DER GIESSEN WJ, LINCOFF AM, SCHWARTZ RS et al.: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 94:1690-1697.
48. FARB A, HELLER PF, SHROFF S et al.: Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation (2001) 104:473-479.
49. DRACHMAN DE, EDELMAN ER, SEIFERT P et al.: Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am. Coll. Cardiol. (2000) 36:2325-2332.
50. FINKELSTEIN A, MCCLEAN D, KAR S et al.: Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation (2003) 107:777-784.
51. SCHELLER B, SPECK U, SCHMITT A, BOHM M, NICKENIG G: Addition of paclitaxel to contrast media prevent restenosis after coronary stent implantation. J. Am. Coll. Cardiol. (2003) 42:1415-1420.
52. HONDA Y, GRUBE E, DE LA FUENTE LM et al.: Novel drug-delivery stent: intravascular ultasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation (2001) 104:380-383.
53. VIRMANI R, LIISTRO F, STANKOVIC G et al.: Mechanism of late in-stent restenosis after implantation of paclitaxel derivate-eluting polymer stent system in humans. Circulation (2002) 106:2644-2651.
54. DRACHMAN DE: Clinical experience with drug-eluting stents. Rev. Cardiovasc. Med. (2002) 3(Suppl. 5):S31-S37.
55. KATAOKA T, GRUBE E, HONDA Y et al.: 7-Hexanoxyl-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the study to compare restenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation (2002) 106:1788-1793.
56. LIISTRO F, STANKOVIC G, DI MARIO C et al.: First: clinical experience with a paclitaxel derivative-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation (2002) 105: 883-1886.
57. GRUBE E, SILBER S, HAUPTMANN KE et al.: TAXUS I Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation (2003) 107:38-42.
58. BULLESFELD L, GERCKENS U, MULLER R, GRUBE E: Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I. Z. Kardiol. (2003) 92:825-832.
59. COLOMBO A, DRZEWIECKI J, BANNING A et al.: Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation (2003) 108:788-794.
60. TANABE K, SERRUYS PW, DEGERTEKIN M et al.: Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: comparison with bare metal stents by serial intravascular ultrasound analyses: data from the randomized TAXUS-II trial. Circulation (2004) 109:196-200.
61. SERRUYS PW, DEGERTEKIN M, TANABE K et al.: Vascular responses at proximal and distal edges of paclitaxel stents: serial intravascular ultrasound analysis from the TAXUS II trial. Circulation (2004) 109:627-633.
62. STONE GW, ELLIS SG, COX DA et al.: A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. (2004) 350:221-231.
63. STONE GW, ELLIS SG, COX DA et al.: One-year clinical results with the slow-release, polymer-based paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 109 16):1942-1947.
64. TANABE K, SERRUYS PW, GRUBE E et al.: TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation (2003) 107:559-564.
65. PARK SJ, SHIM WH, HO DS et al.: A paclitaxel-eluting stent for the prevention of coronary restenosis. N. Engl. J. Med. (2003) 348:1537-1545.
66. HONG M-K, MINTZ GS, LEE CW et al.: Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular analysis from the ASian Paclitaxel-eluting stent clinical trial (ASPECT). Circulation (2003) 107:517-520.
67. GERSHLICK A, DE SCHEERDER I, CHEVALIER B et al.: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of paclitaxel-eluting Stent (ELUTES) trial. Circulation (2004) 109:487-493.
68. LANSKY AJ, COSTA RA, MINTZ GS et al.: Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions. Angiographic follow-up of the deliver clinical trial. Circulation (2004) 109(16):1948-1954.